

# CITATION REPORT

List of articles citing

Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19

DOI: 10.1101/2021.11.30.21266756

»»»

**Source:** <https://exaly.com/paper-pdf/123361930/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	Updates for Health Providers on Monoclonal Antibodies for COVID-19: Promising Adjunct but not Alternative to Vaccinations.. <i>American Journal of Medicine</i> , <b>2022</b> ,	2.4	
3	Real-world Effectiveness of Casirivimab and Imdevimab in Patients With COVID-19 in the Ambulatory Setting: An Analysis of Two Large US National Claims Databases.		0
2	Real-World Effectiveness of Casirivimab and Imdevimab Among Patients Diagnosed With COVID-19 in the Ambulatory Setting: A Retrospective Cohort Study Using a Large Claims Database.		0
1	Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database. <b>2022</b> , 12, e064953		0